# The Military HIV Research Program ( MHRP ) Clinical Trial Unit

> **NIH NIH UM1** · HENRY M. JACKSON FDN FOR THE ADV MIL/MED · 2022 · $42,798

## Abstract

Abstract
COVID-19 Vaccine Clinical Development Team
The USG enterprise to develop and optimize vaccine prevention modalities for SARS CoV-2 incorporates
the DAIDS HVTN as a key partner in strategic development, research prioritization and execution,
landscape analysis for future directions and analysis of outcomes. Dr. Robb has co-chaired and
participated in the USG Vaccine Development Team for clinical research along with the PI and others
within the HVTN. The administrative amendment to CTU funding to HJF will sustain Dr. Robb’s role in
this capacity.

## Key facts

- **NIH application ID:** 10563429
- **Project number:** 3UM1AI108568-09S1
- **Recipient organization:** HENRY M. JACKSON FDN FOR THE ADV MIL/MED
- **Principal Investigator:** Julie A. Ake
- **Activity code:** UM1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $42,798
- **Award type:** 3
- **Project period:** 2022-02-11 → 2022-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10563429

## Citation

> US National Institutes of Health, RePORTER application 10563429, The Military HIV Research Program ( MHRP ) Clinical Trial Unit (3UM1AI108568-09S1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10563429. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*